What might it cost if approval changes the market
She filed a lawsuit in August 2023 against both Novo Nordisk (Ozempics manufacturer) and Eli Lilly (Mounjaros manufacturer)
Conclusion Semaglutide treatment offers a promising option for individuals struggling with type 2 diabetes, obesity, and related cardiovascular risks
J Diabetes Res 2018:1232583 Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V (2020) Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment